Search results
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 5 days agoLast week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular...
Analyst Report: Regeneron Pharmaceuticals, Inc.
Morningstar Research via Yahoo Finance· 16 hours agoRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products ...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 2 hours agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 4 hours agodropped nearly 30% in premarket trading Monday after the company said its experimental...
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)
Seeking Alpha· 3 hours agoEyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 4 days agoThree at-home vision-monitoring tools failed to detect worsening neovascular age-related macular ...
...Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) -...
WTNH-TV New Haven· 6 days agoEluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - Ocular...
Benzinga· 5 days agoTherapeutix, Inc. OCUL "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative ...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 7 days agoHD clinical program during a series of presentations at the Association for Research in Vision and...
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...